MYD88 and primary central nervous system lymphoma: In a phase Ib study, in 18 PCNSL patients with newly diagnosed and R/R PCNSL, including those with CD79B and/or MYD88 mutations, 94% had reduced tumor volume after receiving ibrutinib monotherapy.